[Use of proscar in preoperative preparation of patients with benign prostatic hyperplasia before transureteral resection].
Effects of proskar-MSD used before transurethral resection (TUR) of the prostate in patients with benign prostatic hyperplasia (BPH) were studied with specification of the drug action on hematuria during and after operation. Patients with histologically verified BPH received proskar for 3 and 6 months in a dose of 5 mg/day. Control patients did not receive preoperative proskar. Of patients who received proskar for 3 months, TUR with estimation of the intraoperative blood loss and changes in microcirculation and structure of prostatic tissue induced by proskar was made in 20 patients (mean age 68 years). A 3-month course of proskar reduced prostatic volume and its hyperplasia by 18-20 cm3, on the average. Mean blood loss was about 111 ml vs control 223 ml. Dopplerography revealed consolidation of adenomatous tissue and decline of volumic blood flow in the prostate after 3-month proskar course. Thus, preoperative proskar administration before TUR of prostatic adenoma results in sclerosing of prostatic tissue, decrease of microcirculation manifesting intraoperatively with diminished hematuria and less number of subsequent complications; promotes a favourable outcome of the operation; improves life quality.
Kamalov
A A
AA
Riaboĭ
A V
AV
Ignashin
N S
NS
Karpov
V K
VK
Dorofeev
S D
SD
D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011300:Preoperative Care; D011468:Prostatectomy / Q000379:methods; D011470:Prostatic Hyperplasia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery*; D014463:Ultrasonography
D004791:Enzyme Inhibitors; D018120:Finasteride